drugset / Trial / NCT02386111
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.
Timeline
- Start
- 2015-05
- Primary completion
- 2017-08
- Completion
- 2017-11-03
Outcome
Outcome not reported
Stopped (Business): “Portfolio re-prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 50 mg | — |
| Subject | Varlilumab | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | Varlilumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Varlilumab | Monoclonal antibody | 3 mg/kg | — |